[18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.

[18F]RCCB6 PET/CT achieves 94.2% sensitivity in detecting metastases in clear-cell renal cell carcinoma, outperforming [18F]FDG PET/CT and conventional imaging.

• Why it matters: Accurate detection of metastases in ccRCC is crucial for effective treatment planning, yet existing imaging methods have limited sensitivity and specificity. Improving diagnostic accuracy can significantly impact patient management and outcomes.
• What they did: The study prospectively evaluated [18F]RCCB6 PET/CT in 150 patients with confirmed or suspected ccRCC, comparing its performance to [18F]FDG PET/CT and conventional imaging across 1,221 lesions, with a focus on sensitivity, specificity, and correlation with CD70 expression.
• The result: [18F]RCCB6 PET/CT demonstrated higher sensitivity (90.8% vs. 75.1%) and specificity (81.6% vs. 56.6%) than conventional imaging, and significantly outperformed [18F]FDG PET/CT in sensitivity (90.5% vs. 41.1%) and specificity (81.4% vs. 24.3%), with strong correlation to CD70 expression (r = 0.843).